AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36049498 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive statin regimens
Number of subjects: 154664
Study 36049498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154664
Study 33694294 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Onyx stent
Number of subjects: 1275
Study 33694294 — intervention group
Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 1275
Study 32377159 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic oral suspension group (POSG)
Number of subjects: 150
Study 32377159 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic oral suspension group (POSG) in IL-1β carriers
Number of subjects: 150
Study 32377159 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (PCG)
Number of subjects: 150
Study 34274514 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid 25 mg
Number of subjects: 1218
Study 34274514 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid 10 mg
Number of subjects: 1218
Study 34274514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study 34172544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 60
Study 34172544 — intervention group
Group type: COMPARATOR
Intervention: Care-as-Usual
Number of subjects: 60
Study 33085857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg)
Number of subjects: 243
Study 33085857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 34542952 — intervention group
Group type: EXPERIMENTAL
Intervention: Robuvit® (300 mg)
Number of subjects: 40
Study 34542952 — intervention group
Group type: COMPARATOR
Intervention: Standard management (SM)
Number of subjects: 40
Study 33279940 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (HCT)
Number of subjects: 124
Study 33279940 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy consolidation
Number of subjects: 124
Study 35079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely fatty-infiltrated rotator cuff muscles
Number of subjects: 133
Study 35079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct tendon retraction
Number of subjects: 133
Study 35079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Obvious muscle atrophy
Number of subjects: 133
Study 35079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreparable massive RCT (MRCT)
Number of subjects: 133
Study 35079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Δshear modulus of the ISP
Number of subjects: 133
Study 33645243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy
Number of subjects: 0
Study 33645243 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy
Number of subjects: 0
Study 35682213 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC (3 cycles of 5‐min compression/5‐min reperfusion at 15 mmHg above systolic blood pressure)
Number of subjects: 16
Study 34911068 — intervention group
Group type: EXPERIMENTAL
Intervention: IV analgesics and intrapapillary local anesthetic infiltrations
Number of subjects: 88
Study 34911068 — intervention group
Group type: COMPARATOR
Intervention: IV analgesics
Number of subjects: 88
Study 35085151 — intervention group
Group type: EXPERIMENTAL
Intervention: Online one-day workshop based on cognitive behavioral therapy
Number of subjects: 0
Study 35085151 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 33197403 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV plus sigh (increase in airway pressure to 30 cm H2O for 3 s once per minute)
Number of subjects: 258
Study 33197403 — intervention group
Group type: COMPARATOR
Intervention: PSV alone (no-sigh group)
Number of subjects: 258
Study 33197403 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV plus sigh
Number of subjects: 258
Study 32005058 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib
Number of subjects: 185
Study 34875052 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved water supply, sanitation and hygiene, and improved infant feeding
Number of subjects: 5280
Study 34875052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 5280
Study 34875052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm births
Number of subjects: 5280
Study 34016168 — intervention group
Group type: EXPERIMENTAL
Intervention: CRMRF activated group
Number of subjects: 80
Study 34016168 — intervention group
Group type: COMPARATOR
Intervention: CRMRF deactivated group
Number of subjects: 80
Study 32007138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily
Number of subjects: 870
Study 32007138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 32007138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 870
Study 35477434 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 2
Study 34254280 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU hCG/day
Number of subjects: 81
Study 34254280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 34809626 — intervention group
Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan
Number of subjects: 213
Study 34809626 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study 34009274 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (abatacept, n=17)
Number of subjects: 60
Study 34009274 — intervention group
Group type: COMPARATOR
Intervention: anti‐IL6 receptor (tocilizumab, n=21)
Number of subjects: 60
Study 34009274 — intervention group
Group type: COMPARATOR
Intervention: anti‐TNF (certolizumab‐pegol, n=22)
Number of subjects: 60
Study 34009274 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 60
Study 34009274 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig treatment
Number of subjects: 60
Study 33856325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fluid management (UGFM) using respiratory change of the IVC diameter
Number of subjects: 202
Study 33856325 — intervention group
Group type: COMPARATOR
Intervention: Usual-care strategy
Number of subjects: 202
Study 33856325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fluid management (UGFM)
Number of subjects: 202
Study 35333346 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mifepristone
Number of subjects: 344
Study 35333346 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 344
Study 35333346 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of previous uterine aspirations
Number of subjects: 344
Study 35333346 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minor clinical symptoms (slight vaginal bleeding or some abdominal cramps) at treatment start
Number of subjects: 344
Study 35333346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 344
Study 33371715 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal infiltration of tramadol
Number of subjects: 90
Study 33371715 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal infiltration of bupivacaine
Number of subjects: 90
Study 33371715 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study 33181849 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis chewing gum, chewed twice daily for at least twenty minutes for two weeks
Number of subjects: 60
Study 33181849 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis mouthwash, rinsed twice daily for one minute for two weeks
Number of subjects: 60
Study 33181849 — intervention group
Group type: COMPARATOR
Intervention: Propolis chewing gum
Number of subjects: 60
Study 36396331 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/d
Number of subjects: 14
Study 36396331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 34886156 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home stool collection kit with detailed verbal instruction
Number of subjects: 480
Study 35190411 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted 6-week pulmonary rehabilitation (PR) programme
Number of subjects: 0
Study 34540787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool (pre-cooling with ice slurry ingestion and per-cooling with ice-vest)
Number of subjects: 12
Study 34540787 — intervention group
Group type: COMPARATOR
Intervention: Control (standard PPE without cooling)
Number of subjects: 12
Study 34540787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool
Number of subjects: 12
Study 33759658 — intervention group
Group type: EXPERIMENTAL
Intervention: Short training of the hospital staff aimed at improving the management of patients with cognitive impairment
Number of subjects: 68
Study 33759658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 33310380 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attentional focus group (n = 71)
Number of subjects: 138
Study 33310380 — intervention group
Group type: COMPARATOR
Intervention: External attentional focus group (n = 67)
Number of subjects: 138
Study 32452659 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate tablets (75 mg) under fed conditions
Number of subjects: 132
Study 32452659 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate tablets (75 mg) under fasted conditions
Number of subjects: 132
Study 32452659 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Plavix)
Number of subjects: 132
Study 35717522 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus levofloxacin
Number of subjects: 106
Study 35717522 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 106
Study 33397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture-recapture method using data from National Nosocomial Infection Surveillance System (NNIS) and Health Information Management database (HIM)
Number of subjects: 503
Study 33397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of SSIs post-discharge
Number of subjects: 503
Study 33397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of the most frequently detected bacterium
Number of subjects: 503
Study 33397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time between detection of SSI and discharge
Number of subjects: 503
Study 32724219 — intervention group
Group type: EXPERIMENTAL
Intervention: New sampling method for corneal nerve quantification
Number of subjects: 88
Study 32724219 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method for corneal nerve quantification
Number of subjects: 88
Study 32724219 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure for corneal nerve quantification
Number of subjects: 88
Study 35395868 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 780
Study 35395868 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 780
Study 33835230 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO) with dexamethasone
Number of subjects: 115
Study 33835230 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (GRA) with dexamethasone
Number of subjects: 115
Study 32078078 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing and partner-testing
Number of subjects: 272
Study 35019995 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from physicians
Number of subjects: 690
Study 35019995 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from family and friends
Number of subjects: 690
Study 35019995 — intervention group
Group type: EXPERIMENTAL
Intervention: More pain‐related disability days
Number of subjects: 690
Study 35019995 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse work ability
Number of subjects: 690
Study 34717692 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent ibrutinib 560 mg continuously plus venetoclax ramp-up to 400 mg over 5 weeks
Number of subjects: 21
Study 34323138 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation inductions focusing on health values
Number of subjects: 1056
Study 34323138 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation inductions focusing on general values
Number of subjects: 1056
Study 34323138 — intervention group
Group type: EXPERIMENTAL
Intervention: Essay-based self-affirmation inductions
Number of subjects: 1056
Study 34323138 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire-based self-affirmation inductions
Number of subjects: 1056
Study 33497730 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior Laser Peripheral Iridotomy (LPI)
Number of subjects: 454
Study 33497730 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal or Nasal Laser Peripheral Iridotomy (LPI)
Number of subjects: 454
Study 33497730 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 454
Study 32636324 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 955
Study 32636324 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 955
Study 32636324 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab (dose change from 140 mg to 70 mg)
Number of subjects: 955
Study 32636324 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab (dose change from 70 mg to 140 mg)
Number of subjects: 955
Study 32636324 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab (overall efficacy)
Number of subjects: 955
Study 32636324 — intervention group
Group type: COMPARATOR
Intervention: erenumab
Number of subjects: 955
Study 35435082 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN ResNet 18-based radiomics model
Number of subjects: 513
Study 33198627 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 primer pairs for non-redundant EST-SSRs
Number of subjects: 7
Study 33198627 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 SSRs (10 sequence-verified and 5 unverified)
Number of subjects: 7
Study 33198627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendrogram analysis of 34 individuals representing the seven L. radiata lines
Number of subjects: 7
Study 35881774 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM HI training
Number of subjects: 144
Study 32698694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention visits (up to six visits over 30 months)
Number of subjects: 60
Study 32698694 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 35033048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention consisting of six behavior change strategies and hardware provision (wash basin, bucket with lid, latrine training mat)
Number of subjects: 74
Study 35033048 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention details provided)
Number of subjects: 74
Study 34002560 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with leflunomide tablets, applied at Sanyinjiao (SP 6), Shenshu (BL 23), Zusanli (ST 36) and ashi points, once every other day, three times a week for 8 weeks.
Number of subjects: 60
Study 34002560 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide tablets taken orally, once a day for 8 weeks.
Number of subjects: 60
Study 33413456 — intervention group
Group type: EXPERIMENTAL
Intervention: Meter 1 ‐ Precision Xtra
Number of subjects: 13
Study 33413456 — intervention group
Group type: EXPERIMENTAL
Intervention: Meter 2 ‐ Keto‐Mojo
Number of subjects: 13
Study 616172358 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve neurostimulation using the remede device
Number of subjects: 3
Study 36078289 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Integrated Intermediary Care (CIIC) intervention
Number of subjects: 100
Study 36078289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 34237553 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy (AAT)
Number of subjects: 53
Study 34237553 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 53
Study 32128512 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear stapler technique (Group A)
Number of subjects: 41
Study 34128766 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles Containing Vaccines (MCVs)
Number of subjects: 548
Study 34128766 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 548
Study 33053116 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC transplantation (PBSCT)
Number of subjects: 60
Study 33053116 — intervention group
Group type: COMPARATOR
Intervention: PE (plasma exchange)
Number of subjects: 60
Study 33053116 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF (granulocyte colony‐stimulating factor)
Number of subjects: 60
Study 33053116 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCT (PBSC transplantation)
Number of subjects: 60
Study 35818254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-channel spine endoscopic lumbar discectomy
Number of subjects: 182
Study 35818254 — intervention group
Group type: COMPARATOR
Intervention: Conventional lumbar discectomy
Number of subjects: 182
Study 32642816 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 72
Study 32642816 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 72
Study 36011843 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sector collaborative care for depression
Number of subjects: 980
Study 36011843 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 980
Study 32097252 — intervention group
Group type: EXPERIMENTAL
Intervention: ART delivered three-monthly in CARGs (3MC)
Number of subjects: 4800
Study 32097252 — intervention group
Group type: EXPERIMENTAL
Intervention: ART delivered six-monthly in CARGs (6MC)
Number of subjects: 4800
Study 32097252 — intervention group
Group type: COMPARATOR
Intervention: ART collected three-monthly at facility (3MF)
Number of subjects: 4800
Study 36370907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg with loading dose
Number of subjects: 364
Study 36370907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg without loading dose
Number of subjects: 364
Study 36370907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg
Number of subjects: 364
Study 36370907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200/50 mg in extension period
Number of subjects: 364
Study 36370907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 33579240 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-week behavioral lifestyle intervention
Number of subjects: 60
Study 33579240 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control (self-guided strategies booklet)
Number of subjects: 60
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV exposure (anti-HBc+)
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg+
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination-like profile (anti-HBs+ alone)
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility to HBV
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV isolates classification
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV/HBV co-infection
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: Treponema pallidum infection among HBV exposed prisoners
Number of subjects: 3368
Study 32315810 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of HBV
Number of subjects: 3368
Study 35618567 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBT
Number of subjects: 300
Study 35618567 — intervention group
Group type: COMPARATOR
Intervention: cTURBT
Number of subjects: 300
Study 33826641 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent-based model with refined parameter estimation methods
Number of subjects: 0
Study 36436883 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI/WBT (Behavioral Lifestyle Intervention followed by Well-Being Therapy)
Number of subjects: 83
Study 36436883 — intervention group
Group type: COMPARATOR
Intervention: BLI (Behavioral Lifestyle Intervention)
Number of subjects: 83
Study 33579265 — intervention group
Group type: EXPERIMENTAL
Intervention: Atractylodes lancea extract (AL) at a single oral dose of 1000 mg
Number of subjects: 48
Study 33579265 — intervention group
Group type: EXPERIMENTAL
Intervention: Atractylodes lancea extract (AL) at multiple dosing of 1000 mg for 21 days
Number of subjects: 48
Study 33579265 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐eudesmol
Number of subjects: 48
Study 33579265 — intervention group
Group type: EXPERIMENTAL
Intervention: Atractylodin
Number of subjects: 48
Study 33579265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 35409816 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning-assisted educational videos and traditional techniques (Group B)
Number of subjects: 50
Study 35409816 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods (Group A)
Number of subjects: 50
Study 34130965 — intervention group
Group type: EXPERIMENTAL
Intervention: skills-based VR
Number of subjects: 360
Study 34130965 — intervention group
Group type: EXPERIMENTAL
Intervention: distraction-based VR
Number of subjects: 360
Study 34130965 — intervention group
Group type: COMPARATOR
Intervention: sham VR
Number of subjects: 360
Study 32654111 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 100
Study 32654111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32243274 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 G EBUS needle
Number of subjects: 60
Study 32243274 — intervention group
Group type: COMPARATOR
Intervention: 21 G EBUS needle
Number of subjects: 60